UNRESECTABLE BREAST CANCER
Clinical trials for UNRESECTABLE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE BREAST CANCER trials appear
Sign up with your email to follow new studies for UNRESECTABLE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Tracking a new hope for Tough-to-Treat breast cancer
Disease control Recruiting nowThis study aims to understand how well a targeted drug called trastuzumab deruxtecan works for people with advanced, hard-to-treat breast cancer that has a specific marker (HER2-low). It will follow over 1,100 patients in Europe who are already receiving this drug or standard che…
Matched conditions: UNRESECTABLE BREAST CANCER
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Blood test could tell doctors when to switch cancer drugs
Disease control Recruiting nowThis study is testing whether a simple blood test taken early in treatment can help doctors make better decisions for patients with advanced breast cancer. Patients will receive standard first-line treatment, then have their blood tested after two weeks. If the test shows the tre…
Matched conditions: UNRESECTABLE BREAST CANCER
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New hope for Tough-to-Treat breast cancer: Two-Drug attack targets hidden weakness
Disease control Recruiting nowThis study is testing whether a combination of two existing drugs, tucatinib and trastuzumab, can help control advanced breast cancer that has a specific genetic mutation (called HER3) but is not the usual HER2-positive type. It's for people whose cancer has grown despite trying …
Matched conditions: UNRESECTABLE BREAST CANCER
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC